摘要:
Lyme disease caused by B. burgdorferi and B. garinii has been traditionally treated with antibiotics. However, to eradicate all three morphological forms of Borrelia species such as spirochetes, rounded bodies and biofilm more effective and safe treatment plan is required. In the instant application, Vitamins and Phytobiologicals have been tested for as a short term and long term treatment in vitro and on biofilm. The combination of tested compounds in form of Mix AO seems to be very beneficial in treating Lyme disease caused by B. burgdorferi and B. garinii.
摘要:
A method and technology to display 3D graphical output for a user using body sensor data, personal medical data in real time is disclosed. A consolidated methodology to bring user meaningful life information based on real-time sensor results, analysis, expert Q&As, “What if” scenarios and future emulation all in one artificial intelligence expert system is described. A unique rendering of 3D image of ones organ, cell or subcellular level display related to one's health condition can be visualized on a graphical user interface of a devices or devices. The change of the display from one level such as from organ to cell or cell to subcellular level or vice versa is enabled is disclosed.
摘要:
The invention discloses identification, method of making and therapeutic use of synthetic oligopeptides for the treatment of infectious diseases, in particular tuberculosis. The oligopeptides are designed using virulence mediating protein for Mycobacterium Tuberculosis bacteria. The antibodies may be used for diagnostic and treatment purposes of infectious diseases. In particular, the sequences with SEQ ID 1 to 11 may be used to produce such oligopeptides synthetically. Suppression of activity of mycobacterium tuberculosis may be achieved with oligopeptides analogous to SEQ ID 1 to 11 as a therapeutic drug and/or as a vaccine in a mammal.
摘要翻译:本发明公开了用于治疗感染性疾病,特别是结核病的合成寡肽的鉴定,制备和治疗用途的方法。 使用针对结核分枝杆菌的毒力介导蛋白设计寡肽。 抗体可用于传染病的诊断和治疗目的。 特别地,可以使用具有SEQ ID No.1至11的序列来合成产生这样的寡肽。 抑制结核分枝杆菌的活性可以通过类似于SEQ ID NO.1至11的寡肽作为治疗药物和/或作为哺乳动物的疫苗来实现。
摘要:
The invention discloses novel model of transgenic mammal, a method of crossbreeding transgenic mammal and the use of the transgenic mammal for assessing prevention and/or treatment methods for cardiovascular and other diseases related to lipoprotein(a). The transgenic mammal expresses human apolipoprotein (a) (apo(a)) and human apolipoprotein B-100 (apo B-100) genes and produces human lipoprotein (a), apo (a) and apo B-100 and produces no vitamin C. This novel dual transgenic mammal is the ideal model for testing pharmaceutical compounds for efficacy and usefulness in the prevention and/or treatment of human diseases.
摘要:
A novel integrated system and method for visualizing human physiology, disease and treatment options are described in the instant application. The graphical rendering of the human body is in depth and the user can explore the internal workings of the organs and cells by simply performing a pealing like act using a cursor and the layer as a flap opens up to show the details. A user can click on a specific topic and watch a video, narration or text relevant to the topic of choice. The integrated system provides storage of curated data, social media access and interaction, database storage and analytics to calculate user behavior. This technology may used as an application on any mobile and hardware device.
摘要:
The invention discloses identification and therapeutic use of matrix metalloproteinase oligopeptides, SEQ ID wherein the matrix metalloproteinase oligopeptide is at least one of SEQ ID 7, 11, 12, 18 and 19 and combination thereof. These oligopeptides are bound to antibodies to create an immune response in the subject mammal against the matrix metalloproteinases of various diseases. The instance method is a means of therapeutic intervention against the disease spread created by the matrix metalloproteinases. Further use of these oligopeptide-antibody responses can be extended to any and all diseases that use the matrix metalloproteinases to aid in their pathogenicity.
摘要翻译:本发明公开了基质金属蛋白酶寡肽SEQ ID NO,其中基质金属蛋白酶寡肽是SEQ ID NO.7,11,12,18和19中的至少一个及其组合的基因金属蛋白酶寡肽的鉴定和治疗用途。 这些寡肽与抗体结合以在受试哺乳动物中产生针对各种疾病的基质金属蛋白酶的免疫应答。 实例方法是针对基质金属蛋白酶产生的疾病传播的治疗干预手段。 这些寡肽 - 抗体应答的进一步使用可以扩展到使用基质金属蛋白酶的任何和所有疾病以帮助其致病性。